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Megaloblastic anaemia, diabetes
and deafness in a 2-year-old
child
To the Editor: Megaloblastic anaemic in childhood is usually
caused by dietary folate deficiency or, rarely, congenital
disorders of vitamin B12 or folate metabolism. Thiamine-
responsive megaloblastic anaemia (TRMA) is a rare autosomal-
recessive disorder caused by inactivating mutations of a
thiamine transporter gene.1
We report on a 2-year-old girl referred after 2 episodes of
diabetic ketoacidosis. She was clinically pale and had
sensorineural deafness. Control of her diabetes required 18
units of insulin daily.
Her haemoglobin concentration was 5.4 g/dl, the mean cell
volume 101 fl, and the corrected reticulocyte count 1.4%. There
were oval macrocytes on the blood smear. Red cell folate and
serum vitamin B12 levels were normal. Her bone marrow
aspirate was hypercellular with predominantly erythroid
hyperplasia and trilineage megaloblastic dysplasia. An iron
stain showed numerous ringed sideroblasts (20%).
A provisional diagnosis of TRMA was made and we
administered an intramuscular dose of 100 mg of thiamine,
followed by 50 mg daily by mouth. There was a rapid
reticulocytosis (10.2%) and the haemoglobin concentration
increased to 9.8 g/dl after 14 days. Her daily insulin
requirements fell to 4 units. Unfortunately attempts to
demonstrate apoptosis of fibroblasts in a thiamine-free medium
proved unsuccessful. 
Three years after diagnosis the patient receives 100 mg of
oral thiamine daily, maintains a haemoglobin concentration of
12.2 g/dl and requires only 3 - 5 units of insulin daily. She has
a hearing aid and attends a school for deaf children.
TRMA is the result of mutations of the SLC19A2 gene
(chromosome 1), which codes for a high-affinity thiamine
transporter.2,3 Rapid transport of thiamine by this facilitated
transport system appears to be essential only for
haematopoietic, pancreatic islet and auditory nerve cell
function. Cumulative cell loss via apoptosis explains why the
clinical manifestations are not apparent in early infancy.4
Passive uptake by a separate low-affinity, high-capacity system
appears adequate to protect other tissues from intracellular
thiamine depletion. Hence TRMA patients receiving adequate
dietary thiamine seldom manifest the classic signs of beriberi
(peripheral neuropathy and cardiomyopathy). Thiamine in
pharmacological doses compensates by increasing passive
uptake via the low-affinity system in the affected tissues.
Our patient ran a typical course with a rapid improvement
in the anaemia and a partial response with regard to insulin
requirements on thiamine supplementation, but
characteristically the sensorineural deafness has persisted.1
We suggest that megaloblastic anaemia with normal vitamin
B12 and folate levels should prompt a therapeutic trial of
thiamine, particularly in a deaf and/or diabetic child.
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Sulpiride and breastfeeding
To the Editor: I have been informed by a number of women
that in order to promote the production/flow of breastmilk
their obstetrician-gynaecologist has prescribed sulpiride. The
dosage used is on average 50 mg 3 times a day. The practice of
prescribing sulpiride appears to have become widespread and I
am concerned about the liberal use of a psychotropic agent that
has the potential to affect the newborn infant’s neurobiological
system. 
According to the Maudsley Guidelines all psychotropics pass
into the breastmilk so no decision is risk-free. The Psychotropic
Drug Directory1 states the following: ‘Breast milk is more acidic
than plasma so basic compounds may be retained and
concentrations accumulate. Drug binding to milk protein is less
than to plasma proteins and the higher lipid content of the
‘hind’ milk makes it likely to have a higher drug concentration
than the first half. Milk levels are usually around 1% of
maternal plasma levels, but there have been few formal
studies. Furthermore drugs should be avoided if the infant is
premature (or has renal, hepatic, cardiac or neurological
impairment).’
As sulpiride at low dose acts as a dopaminergic agent it is
likely to have an influence on dopamine release and therefore
receptor synthesis in the newborn. This effect in turn may have
an impact on early neurodevelopment as well as behaviour.
Dopamine as a key neurotransmitter is implicated in a number
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